Clue to Diagnosis: Flagellate Erythema in Anti-MDA5 Antibody-Positive Dermatomyositis in a Patient with Skin of Color

Main Article Content

Ekaterina Korytnikova
Anastasiia Sumenkova
Victor Cazac
Patrick Webster
Charles L. Halasz

Keywords

dermatomyositis , anti-MDA5 antibodies, clinically amyopathic dermatomyositis, flagellate erythema, rapidly progressive interstitial lung disease, DM, CADM, RP-ILD

Abstract

Anti–melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is a rare subtype of clinically amyopathic DM characterized by minimal muscle involvement, variable skin manifestations, and a high risk of rapidly progressive interstitial lung disease (RP-ILD). Atypical skin findings are frequently misdiagnosed, delaying recognition and treatment. We present the case of a 46-year-old Black woman who developed flagellate erythema, facilitating diagnosis of anti-MDA5 DM complicated by RP-ILD. This case highlights the importance of recognizing uncommon skin findings like flagellate erythema, especially in patients with subtle or atypical presentations, and emphasizes the importance of early diagnosis and prompt immunosuppressive therapy to improve clinical outcomes.

References

1. Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:773352. doi:10.3389/fimmu.2021.773352

2. Molina-Ruiz AM, Romero F, Carrasco L, Feltes F, Haro R, Requena L. Amyophatic dermatomyositis presenting as a flagellated skin eruption with positive MDA5 antibodies and thyroid cancer: a real association? Clin Exp Dermatol. 2015;40(8):887-890. doi:10.1111/ced.12674

3. Castillo RL, Femia AN. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. Ann Transl Med. 2021;9(5):436. doi:10.21037/atm-20-5252

4. Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41(6):1021-1036. doi:10.1007/s00296-021-04819-1

5. Peringeth G, Abbi B, Mahmood S. Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy. BMJ Case Rep CP. 2024;17(3):e253960. doi:10.1136/bcr-2022-253960

6. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 2015;67(5):667-672. doi:10.1002/acr.22498

7. Parodi A, Caproni M, Marzano AV, et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol. 2002;82(1):48-51. doi:10.1080/000155502753600894

8. Bhushan P, Manjul P, Baliyan V. Flagellate dermatoses. Indian J Dermatol Venereol Leprol. 2014;80:149. doi:10.4103/0378-6323.129397

9. Watanabe T, Takizawa N, Nagasaka T, et al. Fatal and extensive multiorgan hemorrhages in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: An autopsy case report. Medicine (Baltimore). 2020;99(3):e18600. doi:10.1097/MD.0000000000018600

10. Wongjirattikarn R, Chaowattanapanit S, Choonhakarn C, So-ngern A, Mahakkanukrauh A, Foocharoen C. Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis. Case Rep Dermatol. 2020;12(1):57. doi:10.1159/000506